Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EBT (2016 - 2025)

Historic EBT for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$1.1 million.

  • Harvard Bioscience's EBT rose 7474.95% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.6 million, marking a year-over-year decrease of 30119.78%. This contributed to the annual value of -$11.7 million for FY2024, which is 35637.72% down from last year.
  • As of Q3 2025, Harvard Bioscience's EBT stood at -$1.1 million, which was up 7474.95% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's EBT ranged from a high of $3.4 million in Q2 2022 and a low of -$50.8 million during Q1 2025
  • Over the past 5 years, Harvard Bioscience's median EBT value was -$1.1 million (recorded in 2023), while the average stood at -$4.1 million.
  • Data for Harvard Bioscience's EBT shows a peak YoY increase of 64129.75% (in 2022) and a maximum YoY decrease of 1052222.22% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Harvard Bioscience's EBT stood at $1.1 million in 2021, then plummeted by 178.87% to -$892000.0 in 2022, then decreased by 23.65% to -$1.1 million in 2023, then skyrocketed by 153.49% to $590000.0 in 2024, then plummeted by 292.2% to -$1.1 million in 2025.
  • Its EBT stands at -$1.1 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$50.8 million for Q1 2025.